logo

For the Inventor, By the Inventor

Evry, France

Genethon


USPTO Granted Patents = 59

% Expired Patents = 18.6



Trademarks = 1

Forward Citations = 188

Loading Chart...
Loading Chart...

64 inventors (with patents filed for the assignee):

goldMedal Otto-Wilhelm Merten (10 out of 10 patents)

silverMedal Ana Maria Buj Bello (10 out of 11 patents)

bronzeMedal Isabelle Richard (10 out of 11 patents)

4.  Federico Mingozzi (8 out of 15 patents)

5.  Antoine Kichler (6 out of 8 patents)

6.  Giuseppe Ronzitti (5 out of 5 patents)

7.  Daniel Scherman (5 out of 38 patents)

8.  Monique Van Oers (5 out of 5 patents)

9.  Alan Beggs (5 out of 7 patents)

10.  Martin K Childers (5 out of 7 patents)

11.  Jean-Michel Rozet (5 out of 7 patents)

12.  Isabelle Perrault (5 out of 7 patents)

13.  Josseline Kaplan (5 out of 7 patents)

14.  Xavier Gerard (5 out of 6 patents)

15.  M Arnold Munnich (5 out of 5 patents)


Core Competencies:
Gene Therapy
AAV Vectors
Extracellular Vesicles
Hematopoietic Stem Cells
Dystrophic Muscle Pathologies
Baculovirus Expression Systems
Nucleotide Repeat Expansion Disorders
Muscular Dystrophy
Protein Expression
Gene Delivery
Systemic Treatment
Acid-alpha Glucosidase Variants

59 patents:

1. 12723263 - VECTORS ENCODING A GLUCOSE-6-PHOSPHATASE (G6PASE-A) FOR GENE THERAPY (2026-09-01),
2. 12662512 - CHIMERIC POLYPEPTIDES AND USES THEREOF (2026-06-23),
3. 12637668 - MINI-GDE FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE III (2026-05-26),
4. 12582723 - POLYNUCLEOTIDES ENCODING A HUMAN FKRP PROTEIN (2026-03-24),
5. 12466864 - PRODUCTION OF LARGE-SIZED QUASIDYSTROPHINS USING OVERLAPPING AAV VECTORS (2025-11-11),
6. 12351816 - CNS gene delivery using peripheral administration of AAV vectors (2025-07-08),
7. 12305187 - Acid-alpha glucosidase variants and uses thereof (2025-05-20),
8. 12171843 - Hybrid regulatory elements (2024-12-24),
9. 12098355 - Fluid system for producing extracellular vesicles and related method (2024-09-24),
10. 12037362 - Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropism (2024-07-16),
11. 12023366 - Efficient systemic treatment of dystrophic muscle pathologies (2024-07-02),
12. 12012613 - Genetically engineered hematopoietic stem cell as a platform for systemic protein expression (2024-06-18),
13. 11819478 - Selective gene therapy expression system (2023-11-21),
14. 11767538 - Widespread gene delivery to motor neurons using peripheral injection of AAV vectors (2023-09-26),
15. 11596698 - Synthetic polynucleotides encoding a human FKRP protein (2023-03-07),
GENETHON is a non-profit research and development organization focused on gene therapy. They work towards finding curative solutions for rare genetic diseases. With a team of experts and state-of-the-art facilities, GENETHON conducts cutting-edge research, clinical trials, and supports promising projects in the field of gene therapy. Their ultimate goal is to improve the lives of patients affected by genetic diseases by developing safe and effective gene therapies.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Genethon
59 Patents

#2 in Evry

#421 in France

#12,205 in the World

Evry, FR
Evry, France

Genethon

Forward Citations = 188

64 inventors:

goldMedal Otto-Wilhelm Merten (10 out of 10 patents)

silverMedal Ana Maria Buj Bello (10 out of 11 patents)

bronzeMedal Isabelle Richard (10 out of 11 patents)

4.  Federico Mingozzi (8 out of 15 patents)

5.  Antoine Kichler (6 out of 8 patents)

Please report any incorrect information to [email protected]
Loading…